<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480232</url>
  </required_header>
  <id_info>
    <org_study_id>EVP-6124-014</org_study_id>
    <secondary_id>1R01DA030992-01</secondary_id>
    <nct_id>NCT01480232</nct_id>
  </id_info>
  <brief_title>A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence</brief_title>
  <official_title>Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A. Eden Evins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the initial evidence for efficacy of the investigational
      medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper
      of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been put on clinical hold by FDA
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of EVP-6124 on 7-day Point-prevalence Smoking Abstinence</measure>
    <time_frame>Week 1, 2, 4, 6, 8, 10, 12</time_frame>
    <description>Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) &lt;10 ppm and/or urine cotinine &lt;50 ng/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Expired Carbon Monoxide (CO) Concentration From Baseline to End Point</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6, 8, 10, 12</time_frame>
    <description>CO concentration was measured at every visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of EVP-6124 on Cognitive Performance as Measured by the Continuous Performance Test Hit Reaction Time</measure>
    <time_frame>Baseline, week 1, week 12</time_frame>
    <description>The Continuous Performance Test (CPT) is a measure of both vigilance/attentional control and response inhibition. During the task, subjects are required to press a button whenever a letter appears on the screen unless that letter is an 'X'. Measures of attentional control will serve as primary measure from this test. Baseline attentional impairment is associated with reduced odds of abstinence, abstinence differentially worsens performance on this measure in those with baseline attentional impairment, and NRT improves performance on a similar measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of EVP-6124 Alone or Combined With NRT</measure>
    <time_frame>Weeks 1-12</time_frame>
    <description>All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements. Data was collected at every visit and was analyzed as aggregate at the end of week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of EVP-6124 on Working Memory as Measured by the N-Back Task Reaction Time</measure>
    <time_frame>Baseline, week 1, week 12</time_frame>
    <description>This task is a standard measure that can assess working memory performance under varying levels of task demand. Subjects are presented with a stream of stimuli, and the task is to decide for each stimulus whether it matches the one presented N items before. The processing load can be varied systematically by manipulating the value of N, which is expressed with changes in accuracy and reaction time. The number of errors as well as reaction times increase monotonically with increasing levels of N. The n-back task is sensitive to nicotine administration and abstinence effects. Here we present reaction time (RT)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>EVP-6124 + NicoDerm (Active)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + NicoDerm (Active)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6124 + NRT Patch (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + NRT Patch (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6124</intervention_name>
    <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)</description>
    <arm_group_label>EVP-6124 + NicoDerm (Active)</arm_group_label>
    <arm_group_label>EVP-6124 + NRT Patch (Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>One placebo capsule ingested orally daily for 12 weeks (84 days)</description>
    <arm_group_label>Placebo + NicoDerm (Active)</arm_group_label>
    <arm_group_label>Placebo + NRT Patch (Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NicoDerm Patch (Active)</intervention_name>
    <description>One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).</description>
    <arm_group_label>EVP-6124 + NicoDerm (Active)</arm_group_label>
    <arm_group_label>Placebo + NicoDerm (Active)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRT Patch (Placebo)</intervention_name>
    <description>One NRT patch (Placebo) daily for first 6 weeks (42 days).</description>
    <arm_group_label>EVP-6124 + NRT Patch (Placebo)</arm_group_label>
    <arm_group_label>Placebo + NRT Patch (Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Supportive and Behavioral Treatment</intervention_name>
    <description>Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
    <arm_group_label>EVP-6124 + NicoDerm (Active)</arm_group_label>
    <arm_group_label>Placebo + NicoDerm (Active)</arm_group_label>
    <arm_group_label>EVP-6124 + NRT Patch (Placebo)</arm_group_label>
    <arm_group_label>Placebo + NRT Patch (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self-report of smoking an average of ≥10 cigarettes/day for 6 months and expired
             carbon monoxide (CO) ≥10 parts per million (ppm) or urine cotinine ≥ 100 ng/mL at
             screening or self-report of smoking an average of 5-9 cigarettes/day for 6 months and
             a urine cotinine ≥30ng/ml at screening

          -  Have a negative urine drug screen at screening

          -  Fertile, sexually active subjects (males and females) must use an effective method of
             contraception from the first dose of study drug and for 3 months after the last dose
             of study drug

          -  If female and capable of conception, must have a negative urine Human chorionic
             gonadotrophin (hCG) pregnancy test at screening and Day 1

        Exclusion Criteria:

          -  Have unstable medical illness with hospitalization for treatment likely within 6
             months

          -  Have life-threatening arrhythmia, cerebrovascular or cardiovascular event within 6
             months of enrollment

          -  Have liver function tests elevated &gt;2.5 times the upper limit of normal range

          -  Have a tumor or a seizure disorder

          -  Currently using other tobacco- or nicotine-containing products and unwilling to try to
             quit

          -  Have a 6-month history of substance use disorder other than nicotine or caffeine or
             major depressive disorder

          -  Have a history of multiple adverse drug reactions

          -  Non-response (past 3 months) to nicotine replacement therapy (NRT) &gt;20 mg/day,
             bupropion &gt;150 mg/day, or varenicline 2 mg/day for ≥4 weeks

          -  Use of excluded concomitant medications

          -  Hospitalization for any reason within 30 days of screening

          -  Use of any investigational drug or device within 30 days of screening

          -  Have clinically significant abnormal serum electrolytes

          -  Have insufficiently controlled diabetes mellitus

          -  Have renal insufficiency (serum creatinine &gt;1.8 mg/dL)

          -  Malignant tumor within the last 5 years, with the exception of squamous and basal cell
             carcinoma or cervical carcinoma in situ

          -  Have a clinically significant cardiovascular abnormality on the screening EKG

          -  Lifetime history of schizophrenia, bipolar disorder, post-traumatic stress disorder,
             bulimia, organic mental disorder, dementia, pervasive developmental disorder

          -  Have untreated, clinically significant hypothyroidism or hyperthyroidism

          -  Have a positive self-report of human immunodeficiency virus infection

          -  Females who are pregnant or nursing

          -  Any experimental drug currently or within 30 days before baseline

          -  Have a serious risk of suicide

          -  Have a screening electrocardiogram (ECG) with a corrected QT (QTc) interval using
             Bazett's formula &gt;450 msec for males and &gt;470 msec for females or the presence of any
             clinically significant cardiac abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Eden Evins, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <results_first_submitted>December 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2017</results_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>A. Eden Evins</investigator_full_name>
    <investigator_title>Director, Center for Addiction Medicine Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Nicotinic Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited using advertisements in the local media market.Those who made contact in response to advertisements spoke initially with a research coordinator who provided further information about the study, answered initial questions from the potential subject, and administered a 10-minute questionnaire assessing eligibility.</recruitment_details>
      <pre_assignment_details>Prior to initiation of any study procedures, the informed consent process was conducted by a study physician who explained the study in detail making sure that the subject understood the potential risks/benefits as outlined in the consent form; 350 signed consent, 60 were found ineligible and 130 either withdrew consent or was discontinued</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EVP-6124 + NicoDerm (Active)</title>
          <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm Patch (Active): One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="P2">
          <title>EVP-6124 + NRT Patch (Placebo)</title>
          <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT (nicotine replacement therapy) Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="P3">
          <title>Placebo + NicoDerm (Active)</title>
          <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm Patch (Active): One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="P4">
          <title>Placebo + NRT Patch (Placebo)</title>
          <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EVP-6124 + NicoDerm (Active)</title>
          <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm Patch (Active): One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="B2">
          <title>EVP-6124 + NRT Patch (Placebo)</title>
          <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="B3">
          <title>Placebo + NicoDerm (Active)</title>
          <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm Patch (Active): One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="B4">
          <title>Placebo + NRT Patch (Placebo)</title>
          <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.63" spread="12.17"/>
                    <measurement group_id="B2" value="44.70" spread="13.06"/>
                    <measurement group_id="B3" value="44.03" spread="12.81"/>
                    <measurement group_id="B4" value="45.15" spread="11.42"/>
                    <measurement group_id="B5" value="44.30" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of Regular Smoking</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.31" spread="11.01"/>
                    <measurement group_id="B2" value="26.38" spread="13.24"/>
                    <measurement group_id="B3" value="24.89" spread="12.84"/>
                    <measurement group_id="B4" value="26.46" spread="12.17"/>
                    <measurement group_id="B5" value="25.26" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes Smoked Per Day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.53" spread="9.35"/>
                    <measurement group_id="B2" value="19.41" spread="15.09"/>
                    <measurement group_id="B3" value="22.87" spread="30.63"/>
                    <measurement group_id="B4" value="20.04" spread="13.85"/>
                    <measurement group_id="B5" value="20.21" spread="17.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expired CO, ppm</title>
          <description>Measurements of CO in expired breath was the primary means of biochemical verification of smoking self-report during the study at each study visit. End-expiratory CO levels ≥10 ppm indicate current cigarette use, whereas levels of &lt;10 ppm indicate abstinence.</description>
          <units>parts per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.18" spread="4.17"/>
                    <measurement group_id="B2" value="4.29" spread="2.76"/>
                    <measurement group_id="B3" value="4.78" spread="3.46"/>
                    <measurement group_id="B4" value="4.85" spread="4.38"/>
                    <measurement group_id="B5" value="4.78" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FTND Score</title>
          <description>Fagerström Test for Nicotine Dependence (FTND) will determine the level of nicotine dependence. The scale score ranges from 0 to 10. An FTND score ≥6 indicates high nicotine dependence and a score of &lt;6 indicates a low to moderate level of dependence</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.40" spread="2.07"/>
                    <measurement group_id="B2" value="5.34" spread="2.17"/>
                    <measurement group_id="B3" value="5.39" spread="1.94"/>
                    <measurement group_id="B4" value="5.32" spread="2.07"/>
                    <measurement group_id="B5" value="5.36" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of EVP-6124 on 7-day Point-prevalence Smoking Abstinence</title>
        <description>Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) &lt;10 ppm and/or urine cotinine &lt;50 ng/mL.</description>
        <time_frame>Week 1, 2, 4, 6, 8, 10, 12</time_frame>
        <population>The primary smoking cessation variable is biochemically verified self-report of 7-day point prevalence abstinence at 12 weeks (end of treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 + NicoDerm CQ (Active)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 + NRT Patch (Placebo)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + NicoDerm CQ (Active)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + NRT Patch (Placebo)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of EVP-6124 on 7-day Point-prevalence Smoking Abstinence</title>
          <description>Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) &lt;10 ppm and/or urine cotinine &lt;50 ng/mL.</description>
          <population>The primary smoking cessation variable is biochemically verified self-report of 7-day point prevalence abstinence at 12 weeks (end of treatment).</population>
          <units>% participants with 7-Day Point Prevalen</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="28.9"/>
                    <measurement group_id="O4" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5"/>
                    <measurement group_id="O2" value="19.5"/>
                    <measurement group_id="O3" value="42.1"/>
                    <measurement group_id="O4" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="44.7"/>
                    <measurement group_id="O4" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5"/>
                    <measurement group_id="O2" value="14.6"/>
                    <measurement group_id="O3" value="34.2"/>
                    <measurement group_id="O4" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="14.6"/>
                    <measurement group_id="O3" value="28.9"/>
                    <measurement group_id="O4" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="23.7"/>
                    <measurement group_id="O4" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seven-Day Point Prevalence Abstinence Rate week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="18.4"/>
                    <measurement group_id="O4" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Expired Carbon Monoxide (CO) Concentration From Baseline to End Point</title>
        <description>CO concentration was measured at every visit.</description>
        <time_frame>Baseline, Weeks 1, 2, 4, 6, 8, 10, 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 + NicoDerm CQ (Active)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 + NRT Patch (Placebo)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + NicoDerm CQ (Active)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + NRT Patch (Placebo)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Expired Carbon Monoxide (CO) Concentration From Baseline to End Point</title>
          <description>CO concentration was measured at every visit.</description>
          <units>part per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="11"/>
                    <measurement group_id="O2" value="17.2" spread="9.8"/>
                    <measurement group_id="O3" value="20.5" spread="13.7"/>
                    <measurement group_id="O4" value="19.3" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="11"/>
                    <measurement group_id="O2" value="9.2" spread="10.1"/>
                    <measurement group_id="O3" value="5.2" spread="6"/>
                    <measurement group_id="O4" value="8.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="11.5"/>
                    <measurement group_id="O2" value="10.1" spread="10.2"/>
                    <measurement group_id="O3" value="4.9" spread="5.4"/>
                    <measurement group_id="O4" value="8.5" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="7.7"/>
                    <measurement group_id="O2" value="9.8" spread="11.5"/>
                    <measurement group_id="O3" value="6.3" spread="7.9"/>
                    <measurement group_id="O4" value="9.6" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="11.4"/>
                    <measurement group_id="O2" value="12.7" spread="16.3"/>
                    <measurement group_id="O3" value="5.3" spread="5.7"/>
                    <measurement group_id="O4" value="7.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="10.5"/>
                    <measurement group_id="O2" value="12.6" spread="16.8"/>
                    <measurement group_id="O3" value="7.5" spread="6.4"/>
                    <measurement group_id="O4" value="7.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="10.9"/>
                    <measurement group_id="O2" value="11.2" spread="11.9"/>
                    <measurement group_id="O3" value="8.2" spread="7.4"/>
                    <measurement group_id="O4" value="5.3" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="8.7"/>
                    <measurement group_id="O2" value="11.4" spread="13.6"/>
                    <measurement group_id="O3" value="9" spread="8.1"/>
                    <measurement group_id="O4" value="8.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of EVP-6124 on Cognitive Performance as Measured by the Continuous Performance Test Hit Reaction Time</title>
        <description>The Continuous Performance Test (CPT) is a measure of both vigilance/attentional control and response inhibition. During the task, subjects are required to press a button whenever a letter appears on the screen unless that letter is an ‘X’. Measures of attentional control will serve as primary measure from this test. Baseline attentional impairment is associated with reduced odds of abstinence, abstinence differentially worsens performance on this measure in those with baseline attentional impairment, and NRT improves performance on a similar measure.</description>
        <time_frame>Baseline, week 1, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 + NicoDerm CQ (Active)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 + NRT Patch (Placebo)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + NicoDerm CQ (Active)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + NRT Patch (Placebo)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of EVP-6124 on Cognitive Performance as Measured by the Continuous Performance Test Hit Reaction Time</title>
          <description>The Continuous Performance Test (CPT) is a measure of both vigilance/attentional control and response inhibition. During the task, subjects are required to press a button whenever a letter appears on the screen unless that letter is an ‘X’. Measures of attentional control will serve as primary measure from this test. Baseline attentional impairment is associated with reduced odds of abstinence, abstinence differentially worsens performance on this measure in those with baseline attentional impairment, and NRT improves performance on a similar measure.</description>
          <units>mili seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Hit RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.26" spread="78.15"/>
                    <measurement group_id="O2" value="434.72" spread="65.40"/>
                    <measurement group_id="O3" value="427.76" spread="66.87"/>
                    <measurement group_id="O4" value="423.94" spread="72.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 Hit RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="424.77" spread="76.85"/>
                    <measurement group_id="O2" value="429.99" spread="59.94"/>
                    <measurement group_id="O3" value="418.74" spread="60.32"/>
                    <measurement group_id="O4" value="407.97" spread="68.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Hit RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.73" spread="71.59"/>
                    <measurement group_id="O2" value="421.66" spread="67.67"/>
                    <measurement group_id="O3" value="432.56" spread="73.91"/>
                    <measurement group_id="O4" value="396.78" spread="53.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of EVP-6124 Alone or Combined With NRT</title>
        <description>All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements. Data was collected at every visit and was analyzed as aggregate at the end of week 12</description>
        <time_frame>Weeks 1-12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 + NicoDerm CQ (Active)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 + NRT Patch (Placebo)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + NicoDerm CQ (Active)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + NRT Patch (Placebo)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of EVP-6124 Alone or Combined With NRT</title>
          <description>All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements. Data was collected at every visit and was analyzed as aggregate at the end of week 12</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of EVP-6124 on Working Memory as Measured by the N-Back Task Reaction Time</title>
        <description>This task is a standard measure that can assess working memory performance under varying levels of task demand. Subjects are presented with a stream of stimuli, and the task is to decide for each stimulus whether it matches the one presented N items before. The processing load can be varied systematically by manipulating the value of N, which is expressed with changes in accuracy and reaction time. The number of errors as well as reaction times increase monotonically with increasing levels of N. The n-back task is sensitive to nicotine administration and abstinence effects. Here we present reaction time (RT)</description>
        <time_frame>Baseline, week 1, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 + NicoDerm CQ (Active)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 + NRT Patch (Placebo)</title>
            <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O3">
            <title>Placebo + NicoDerm CQ (Active)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm CQ patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm CQ Patch (Active): One NicoDerm CQ patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
          <group group_id="O4">
            <title>Placebo + NRT Patch (Placebo)</title>
            <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of EVP-6124 on Working Memory as Measured by the N-Back Task Reaction Time</title>
          <description>This task is a standard measure that can assess working memory performance under varying levels of task demand. Subjects are presented with a stream of stimuli, and the task is to decide for each stimulus whether it matches the one presented N items before. The processing load can be varied systematically by manipulating the value of N, which is expressed with changes in accuracy and reaction time. The number of errors as well as reaction times increase monotonically with increasing levels of N. The n-back task is sensitive to nicotine administration and abstinence effects. Here we present reaction time (RT)</description>
          <units>mili seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 2-Back RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="634.04" spread="166.51"/>
                    <measurement group_id="O2" value="645.01" spread="180.83"/>
                    <measurement group_id="O3" value="632.80" spread="176.78"/>
                    <measurement group_id="O4" value="616.33" spread="186.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 3-Back RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667.75" spread="202.35"/>
                    <measurement group_id="O2" value="642.89" spread="182.20"/>
                    <measurement group_id="O3" value="620.55" spread="210.04"/>
                    <measurement group_id="O4" value="600.78" spread="179.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 2-Back RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="578.58" spread="101.86"/>
                    <measurement group_id="O2" value="619.42" spread="174.86"/>
                    <measurement group_id="O3" value="565.84" spread="148.24"/>
                    <measurement group_id="O4" value="553.90" spread="135.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 3-Back RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635.08" spread="164.16"/>
                    <measurement group_id="O2" value="627.85" spread="180.06"/>
                    <measurement group_id="O3" value="608.94" spread="152.38"/>
                    <measurement group_id="O4" value="586.15" spread="173.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 2-Back RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608.03" spread="145.92"/>
                    <measurement group_id="O2" value="620.28" spread="175.61"/>
                    <measurement group_id="O3" value="598.47" spread="156.28"/>
                    <measurement group_id="O4" value="565.41" spread="149.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 3-Back RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="639.51" spread="175.91"/>
                    <measurement group_id="O2" value="613.75" spread="176.40"/>
                    <measurement group_id="O3" value="611.85" spread="185.75"/>
                    <measurement group_id="O4" value="585.15" spread="177.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>week 1 to week 12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EVP-6124 + NicoDerm (Active)</title>
          <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NicoDerm Patch (Active): One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="E2">
          <title>EVP-6124 + NRT Patch (Placebo)</title>
          <description>One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
EVP-6124: One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="E3">
          <title>Placebo + NicoDerm (Active)</title>
          <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NicoDerm Patch (Active): One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
        <group group_id="E4">
          <title>Placebo + NRT Patch (Placebo)</title>
          <description>One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
Placebo Capsule: One placebo capsule ingested orally daily for 12 weeks (84 days)
NRT Patch (Placebo): One NRT patch (Placebo) daily for first 6 weeks (42 days).
Brief Supportive and Behavioral Treatment: Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis Flare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatine phosphokinase (CPK)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Increase appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abnormal sleeping pattern</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold/flu</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressive symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation at Patch Site</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A. Eden Evins, MD, MPH</name_or_title>
      <organization>Massachusetts General Hospital-Center for Addiction Medicine</organization>
      <phone>617-643-4679</phone>
      <email>aeevins@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

